Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Ann Rheum Dis.

Ozen S, Ben-Cherit E, Foeldvari I, Amarilyo G, Ozdogan H, Vanderschueren S, Marzan K, Kahlenberg JM, Dekker E, De Benedetti F, Koné-Paut I

doi: 10.1136/annrheumdis-2020-217419.

Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial

JAMA Dermatol.

Koenig MK, Bell CS, Hebert AA, Roberson J, Samuels JA, Slopis JM, Tate P, Northrup H; TREATMENT Trial Collaborators

doi: 10.1001/jamadermatol.

Juvenile Idiopathic Arthritis

Efficacy and Safety of Canakinumab in sJIA Patients with and without Fever at Baseline: Results from an Open-label, Active Treatment Extension Study

Arthritis Rheumatol.

Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, Schneider R, Wulffraat NM, Chasnyk V, Tirosh I, Kallinich T, Kuemmerle-Deschner J, Wouters C, Lauwerys B, Nikishina I, Trachana M, Vougiouka O, Martini A, Lovell DJ, Levy J, Vritzali E, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG).

doi: 10.1002/art.41436.

Melanoma and Skin Cancer

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Eur J Cancer

Umeda Y, Yoshikawa S, Kiniwa Y, Maekawa T, Yamasaki O, Isei T, Matsushita S, Nomura M, Nakai Y, Fukushima S, Saito S, Takenouchi T, Tanaka R, Kato H, Otsuka A, Matsuya T, Baba N, Nagase K, Inozume T, Onuma T, Kuwatsuka Y, Fujimoto N, Kaneko T, Onishi M, Namikawa K, Yamazaki N, Nakamura Y

doi: 10.1016/j.ejca.2021.08.034

Rheumatoid Arthritis

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

Lancet.

Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S

doi: 10.1016/

COMMENTED

Further Publications Dermatology

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

★ 2 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet

Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT

doi: 10.1016/S0140-6736(21)01324-6

COMMENTED

Spinal Disorders

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Lancet.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group

doi: 10.1016/S0140-

Systemic Lupus Erythematosus

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus

Lupus.

Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y

doi: 10.1177/0961203317749047.

Rosacea

Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial

J Drugs Dermatol.

Kircik LH, DuBois J, Draelos ZD, Werschler P, Grande K, Cook-Bolden FE, Weng E, Berk DR, Ahluwalia G

Related content